NCT02522481 - Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-141 | Biotech Hunter

Enrollment

175

Participants

Timeline

Start Date

September 24, 2015

Primary Completion Date

November 7, 2017

Study Completion Date

February 25, 2018

Conditions

Coronary Artery Disease

Interventions

DRUG

Lumason

Lumason (sulfur hexafluoride-type A microspheres) an ultrasound contrast agent was administered as 2 single 2-mL IV injections during rest and stress echocardiography

Trial Locations (17)

10029

Mount Sinai Medical Center, New York

10117

Medizinische Klinik m.S. Kardiologie und Angiologie, Charité Universitätsmedizin Berlin, Berlin

19713

Cardiology Physicians, PA, Newark

43126

Azienda Ospedaliera Universitaria Parma, Parma

44534

Klinikum Lünen, St. Marien-Hospital GmbH, Lünen

46250

Community Heart and Vascular Community Hospital East, Indianapolis

55131

Universitätsmedizin Mainz, Mainz

64111

St. Luke's Mid-America Heart Institute, Kansas City

64116

North Kansas City Hospital, North Kansas City

81379

Kardiologie Klinik Dr. Müller GmbH, Peter Osypka Heart Center, Munich

85724

Sarver Heart Center, University of Arizona, Tucson

91037

Interventional Cardiology Medical Group, Inc., West Hills

92037

University of California San Diego, La Jolla

07960

Morristown Medical Center, Morristown

07666

The Institute for Clinical Research Holy Name Medical Center, Teaneck

T6G2B7

Mazankowski Alberta Heart Institute, University of Alberta Hospital, Edmonton

00161

Azienda Policlinico Umberto I Università degli Studi di Roma La Sapienza, Rome